Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) CEO Vishwas Seshadri sold 25,000 shares of the company's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $4.78, for a total value of $119,500.00. Following the transaction, the chief executive officer now owns 1,355,322 shares of the company's stock, valued at approximately $6,478,439.16. This trade represents a 1.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Abeona Therapeutics Stock Performance
Abeona Therapeutics stock opened at $4.76 on Tuesday. Abeona Therapeutics Inc has a 1 year low of $3.05 and a 1 year high of $8.45. The company has a market cap of $231.02 million, a PE ratio of -1.77 and a beta of 1.79. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The company's 50-day moving average is $5.41 and its two-hundred day moving average is $5.81.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.19. Equities analysts anticipate that Abeona Therapeutics Inc will post -1.16 earnings per share for the current year.
Institutional Investors Weigh In On Abeona Therapeutics
Several large investors have recently modified their holdings of the business. Wellington Management Group LLP bought a new stake in Abeona Therapeutics in the 4th quarter valued at $520,000. Western Standard LLC grew its stake in shares of Abeona Therapeutics by 22.8% during the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock worth $11,610,000 after acquiring an additional 386,321 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Abeona Therapeutics during the 4th quarter worth approximately $67,000. Twinbeech Capital LP acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at approximately $58,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Abeona Therapeutics in the fourth quarter worth $362,000. 80.56% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on ABEO shares. HC Wainwright restated a "buy" rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Monday, March 24th. Oppenheimer began coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 target price on the stock. Finally, StockNews.com raised Abeona Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, March 24th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $17.50.
Get Our Latest Analysis on Abeona Therapeutics
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
